Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients
|
|
- Jodie Crawford
- 6 years ago
- Views:
Transcription
1 Powered by Website address: Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients Since January 2015, Tübingen has been home to a Centre for Personalised Medicine (ZPM). Twenty-three institutes and hospitals have joined forces to improve diagnosis of disease and develop individualised treatments for patients with a variety of diseases. In parallel, the centre also develops new diagnostic strategies. This means, for example, that data derived from the analysis of the entire genetic material of cells, proteins and metabolic processes are taken into account when stratifying patient therapy. Treatment of a tumour patient: molecular diagnostic procedures and bioinformatic analyses are used to identify genes that promote the development of tumours. Based on this information, potential target structures are identified by interdisciplinary boards. University Hospital Tübingen "It is not that easy to sum up what personalised medicine actually is," says Prof. Dr. Nisar Malek, director of the ZPM, going on to add that the Centre has in fact three main goals. "On the one hand, we hope to be able to increase our understanding of diseases with the diagnostic possibilities offered by state-ofthe-art 'omics' technologies. On the other hand, we also want to use functional imaging methods to improve diagnoses on an individual patient level. This includes more accurate companion diagnostics tests that enable us to react much earlier than before to changes in disease progression. Finally, we want to combine the results from omics analyses, imaging and clinical findings in order to determine the optimal treatment approach for patient groups or individual patients," explains Malek. The interdisciplinary experience of the 23 departments and institutes of the University of Tübingen's Medical Faculty that come together in the ZPM is key to making this project work. Malek sees the comprehensive approach, which involves virtually all medical disciplines, the natural sciences and information technologies, as one of the ZPM's key selling points. 1
2 Currently, Germany only has a handful personalised medicine centres, with most of the centres only focusing on one specific topic. We hope that our approach will take us to the forefront of research into the causes of disease in individuals and the development and testing of individualised treatments," he concludes. Biological methods are key to individualised medicine In order to effectively and optimally integrate omics data, i.e. data derived from the analysis of the entire genetic material of cells ( genomics), proteins ( proteomics) and all metabolic processes (metabolomics) into diagnosis and therapy, the centre has secured the support of the Centre for Quantitative Biology (QBIC). Organigramme of the ZPM showing the competences of its individual research areas. ZPM, University of Tübingen The Centre for Quantitative Biology (QBIC) at the University of Tübingen is headed up by Prof. Dr. Oliver Kohlbacher. The centre pools data produced in the University of Tübingen's hospitals and research institutes with state-of-the-art, high-throughput technologies. The QBIC team analyses and prepares the data for the ZPM. Imaging data are provided by the Department of Preclinical Imaging and Radiopharmacy led by Prof. Dr. Bernd Pichler. Pichler's team is developing pioneering technologies such as a device that combines PET (positron emission tomography) and MRI (magnetic resonance imaging) and provides highly accurate images and information from inside the body. "To be able to quickly and simply link imaging data with omics data, we are establishing a new database in which anonymised patient data are stored ontologically. In June 2015, our hospitals will activate the first accounts. We are currently providing the patients with the information that is necessary to make an informed consent," says Malek. His vision: such models will in future provide the basis for the optimal treatment of patients predisposed to a particular disease. In the case of heart failure, this concept will be able to identify drugs that have the greatest chance of success in a particular patient, either on their own or in combination with other drugs. However, this concept does not fit into the current medical treatment approval and reimbursement system. Malek explains this using cancer treatment as an example. "Suppose we have a patient with cholangiocarcinoma, and we then simulate therapy using all 30,000 2
3 The ZPM is establishing its own database that will be made available to all hospitals within the ZPM. Anonymised patient data stored in the database are used for finding an optimal therapy for a specific disease. ZPM, University of Tübingen drugs approved for human treatment. If the simulation suggests that the patient would best respond to substance XY, this particular drug may well be approved for a number of tumours, but unfortunately not or not yet for the treatment of cholangiocarcinoma." A few demonstrator projects are already underway, ranging from heart failure and eye diseases to different types of cancers. The projects were originally initiated by the Clinical Research platform established by the University's institutional strategy under the German government's Excellence Initiative. They now come under the ZPM. Malek uses heart failure to explain how the Centre works. "We have established so-called Molecular Boards in order to gain an understanding of heart muscle diseases on all levels. We are, for example, looking at the constellation of patients in order to find out why they became ill. High-throughput genetic screening and sequencing is thus used in genetic and molecular analyses of patient DNA. In addition, we also use omics data and information derived from PET/ CT and PET/ MRI images. Using mathematical models across several orders of magnitude helps us correlate the different parameters with each other," says Malek. A revolution in the entire healthcare system Malek is convinced that in the not-too-distant future doctors will experience a paradigm change in the diagnosis and therapy of diseases. He also believes that the procedure for obtaining marketing authorisation for drugs will have to be completely revamped. "The current principles of obtaining drug approval will no longer work in cases where it is impossible to recruit the necessary number of patients with a specific gene signature. Pesonalised medicine will change the diagnosis and treatment of disease forever, and this will affect all areas. Health insurance companies will also have to deal with new challenges and we are trying to sensitise them for the upcoming changes. It goes without saying that patients' associations will then also require healthcare providers to change their way of dealing with reimbursement and other issues." However, Malek does not believe that the cost system itself is at risk. "The common belief that personalised medicine will lead to dramatically rising costs is definitely not right. Just think about the horrendous cost of medicines and treatments that have little or no effect; therapies tailored to the requirements of individual patients would avoid such costs." Malek also stresses that personalised medicine, along with its full arsenal of analytical methods, will not be used for all diseases. There is no reason to use personalised medicine in the case of monocausal diseases. It would be too expensive. Simple bacterial diseases can easily be treated with antibiotics; the application of individualised analyses would disproportionate to the benefits. Precise understanding of the cause of a bacterial infection is not necessary in order to treat it successfully. 3
4 However, when it comes to complex diseases, the situation is different. In fact, complex analyses are very important when it comes to conditions with various causes. Malek explains why, again using cancer as an example. "A cancer such as pancreatic cancer involves a large number of different cells, and we basically need to treat many diseases simultaneously on the molecular level. Therefore, knowledge and experience from widely differing research fields need to be integrated in order to develop new, individual treatments. The one size fits all rule where, for example, broad-spectrum antibiotics are used, cannot be applied to cancers and other diseases that have several causes. However, in order to treat three or four problems simultaneously, individualised medicine is definitely the way to go." Prof. Dr. Nisar Malek has been medical director of the Department of Internal Medicine I at Tübingen University Hospital since His work centres particularly on gastrointestinal and liver diseases. Tübingen University Hospital Centre for Personalised Medicine - ZPM The University of Tübingen's ZPM consists of five research areas: I High-Throughput Methods Speaker: Prof. Dr. Olaf Rieß, Institute of Medical Genetics and Applied Genomics II Complex Diagnostics Speaker: Prof. Dr. Oliver Kohlbacher, Centre for Bioinformatics, Centre for Quantiative Biology and Department of Computer Science III Functional and Molecular Imaging Speaker: Prof. Dr. Bernd Pichler, Institute for Preclinical Imaging and Radiopharmacy IV Therapy Design Speaker: Prof. Dr. Lars Zender, Department of Internal Medicine 1 and Section for Gastrointestinal Oncology V Experimental Therapy Speaker: Prof. Dr. Nisar P. Malek, Department of Internal Medicine 1 4
5 Article 15-Jun-2015 leh BioRegio STERN BIOPRO Baden-Württemberg GmbH Further information Prof. Dr. Nisar Malek Department of Internal Medicine 1 University and University Hospital of Tübingen - ZPM Otfried-Müller-Str. 10 Phone: +49 (0)7071/ nisar.malek(at)med.uni-tuebingen.de ZPM Tübingen The article is part of the following dossiers The era of personalised medicine is dawning 5
CeGaT: DNA and RNA sequencing specialist
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/cegat-dna-and-rna-sequencingspecialist/ CeGaT: DNA and RNA sequencing specialist Sequencing service providers are facing
More informationSoil bacteria to produce new antibiotics
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/soil-bacteria-to-produce-newantibiotics/ Soil bacteria to produce new antibiotics An ever-growing number of genomes of
More information- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationA New Era of Clinical Diagnostics: How the Business Model is Changing.
A New Era of Clinical Diagnostics: How the Business Model is Changing. Nancy J Kelley, President and CEO of Nancy J Kelley & Associates Remarks to BTIG Emerging Technologies in Healthcare Diagnostics September
More informationTerminology for personalized medicine
Terminology for personalized medicine Sarah Ali-Khan 1 PhD, Stephanie Kowal 2, Westerly Luth 2, Richard Gold 1 SJD, and Tania Bubela 2 PhD JD 1. Centre for Intellectual Property Policy (CIPP), Faculty
More informationNordic Common Strengths and Future Potential in the Field of Personalised Medicine
Nordic Common Strengths and Future Potential in the Field of Personalised Medicine NOS-M Workshop 23rd November 2016 Stockholm Waterfront Johan Nilsson Coordinator Medicine and Health Swedish Research
More informationGenomics and personalised medicine
Genomics and personalised medicine Dr Tom Fowler, Deputy Chief Scientist & Director of Public Health WHO Symposium on the Future of Digital Health Systems in the European Region February 2019 About me
More informationUniversity of Athens - Medical School. pmedgr. The Greek Research Infrastructure for Personalized Medicine
University of Athens - Medical School pmedgr The Greek Research Infrastructure for Personalized Medicine - George Kollias - Professor of Experimental Physiology, Medical School, University of Athens President
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More information17th EHFG Electing Health The Europe We Want!
01 03 October 2014 17th EHFG Electing Health The Europe We Want! For more information about the final programme, speakers or the EHFG conference please contact us directly! Follow us on our social media
More informationA whole-system approach to delivering personalised medicine and health in Leeds. Mike Messenger
A whole-system approach to delivering personalised medicine and health in Leeds Mike Messenger Capacity and Resource What is the challenge? In 2016, we face the most significant challenges for a generation.
More informationBOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.
Paper: PB.24.09.15/05 Title: Personalised Medicine Strategy. From: Sir Bruce Keogh, National Medical Director. BOARD PAPER - NHS ENGLAND Purpose of Paper: To inform the Board of the development of an NHS
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationFrumkin, 2e Part 1: Methods and Paradigms. Chapter 6: Genetics and Environmental Health
Frumkin, 2e Part 1: Methods and Paradigms Chapter 6: Genetics and Environmental Health Genetics Genetics, the study of individual genes, has expanded to include genomics, which is the study of all the
More informationPATIENT STRATIFICATION. 15 year A N N I V E R S A R Y. The Life Sciences Knowledge Management Company
PATIENT STRATIFICATION Treat the Individual with the Knowledge of All BIOMAX 15 year A N N I V E R S A R Y The Life Sciences Knowledge Management Company Patient Stratification Tailoring treatment of the
More informationMolecule-specific diagnosis of metabolic diseases
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/molecule-specific-diagnosis-ofmetabolic-diseases/ Molecule-specific diagnosis of metabolic diseases Lysosomal storage diseases
More informationVision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University
Vision, aims and strategies Department of Immunology, Genetics and Pathology Uppsala University April19,2011 SCOPEOFACTIVITIESATIGP Research at the Department focuses on translational medicine through
More informationA bold vision for 2025
Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Annual Stanford Medicine Population Health Sciences Colloquium October 26, 2015
More informationE&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
More informationThe Power to Cure: Therapeutic Innovation in Academia
The Power to Cure: Therapeutic Innovation in Academia Leslie Molony, Ph.D. November 7, 2011 Sanford-Burnham Medical Research Institute: a Non Profit Basic Research Institute Santa Barbara Est. 2006 La
More informationAll research lines at the LMU have a strong methodological focus
Content: Genetic Epidemiology and Statistical Genetics in Complex Diseases... 2 Molecular Epidemiology of Complex Phenotypes... 2 Clinical Trials and Translational Medicine... 3 Clinical Epidemiology and
More informationUp Close and Personal
Special Report Up Close and With Personal advances in genetics, a new type of medicine has emerged: one that s tailored just for you and your DNA. Could it transform the paradigm of how we treat and prevent
More informationUAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE
UAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE advanced diagnostics for advancing cure Multiple myeloma (myeloma) is a complex cancer that can be diffcult to diagnose and challenging to treat. Every case
More informationProtein research and bioinformatics
Protein research and bioinformatics LauritzenConsulting Content and application Proteins are the fundamental building blocks of life. Research in Greater Copenhagen focuses on the significance of proteins
More informationto precision medicine
QIAGEN at the AMP 2018 Annual Meeting yourpath Discover to precision medicine Sample to Insight Discover your path to precision medicine Lead the way with QIAGEN, from Sample to Insight Every day, data
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationChallenges of Personalized Health for Clinical Medicine. Peter J Meier-Abt Swiss Academy of Medical Sciences (SAMS) Berne, Switzerland
Challenges of Personalized Health for Clinical Medicine Peter J Meier-Abt Swiss Academy of Medical Sciences (SAMS) Berne, Switzerland Personalisierte Medizin Personalisierte Gesundheit Personalisierte
More informationGenomic Medicine in France
Genomic Medicine in France Catherine Nguyen, PhD Director ITMO GGB Genetic, Genomic & Bioinformatic Advancing Disease Modeling in Animal-Based research in Support of Precision Medecine: a Workshop ILAR
More informationPioneering Clinical Omics
Pioneering Clinical Omics Clinical Genomics Strand NGS An analysis tool for data generated by cutting-edge Next Generation Sequencing(NGS) instruments. Strand NGS enables read alignment and analysis of
More informationWhat is Precision Medicine?
Precision Medicine Precision Medicine describes the delivery of the right treatment to the right person at the right time. It has the power to improve health outcomes by using technology and data to tailor
More informationKonica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion
News Release Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion Advances Konica Minolta strategy to establish a leadership position in precision medicine Contributes
More informationInformation Technology for Genetic and Genomic Based Personalized Medicine. Submitted. April 23, 2008
Information Technology for Genetic and Genomic Based Personalized Medicine Submitted April 23, 2008 By The Harvard Medical School Partners HealthCare Center for Genetics and Genomics in Partnership with
More informationTrend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital Handling of the early stage is important for
More informationYOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING
YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING THE NEW STANDARD OF CARE WHY GENETIC TESTING? Genetic testing makes it possible to know a priori how your patients will metabolize a specific drug. It is
More informationImportance of Research on Rare Diseases and Orphan Drugs
Importance of Research on Rare Diseases and Orphan Drugs Introduction There are significant moral, scientific, economic and policy imperatives for conducting research into rare diseases. A rare disease
More informationCustomer Case Study. Using Big Data Analytics to Create Better Outcomes for Cancer Patients
Customer Case Study Using Big Data Analytics to Create Better Outcomes for Cancer Patients Cancer is responsible for the early deaths of millions of people worldwide each year. In Germany alone, more than
More informationBioscientists Do you have the Bayer Spirit?
CropScience HealthCare MaterialScience Business Services Industry Services Technology Services www.mybayerjob.com Bioscientists Do you have the Bayer Spirit? Research and Development, Screening, Toxicology,
More informationMaking the case for Personalised Medicine
Making the case for Personalised Medicine The biopharmaceutical industry perspective Barbara Freischem Executive Director European Biopharmaceutical Enterprises Who we are EBE represents the voice of biopharmaceutical
More informationYour story is unique. Diet & Exercise. Environment. Your health. Lifestyle. Genetics A PICTURE OF YOUR HEALTH
What s your story? Your story is unique It s a complex intersection of where you ve come from, and where your everyday choices are taking you. Optimal health choices for you might be different from others.
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationExam MOL3007 Functional Genomics
Faculty of Medicine Department of Cancer Research and Molecular Medicine Exam MOL3007 Functional Genomics Tuesday May 29 th 9.00-13.00 ECTS credits: 7.5 Number of pages (included front-page): 5 Supporting
More informationCOPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES
COPE CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES FAQs This brochure addresses FAQ and is prepared solely for the German market. Local adjustments may be necessary. Please contact us if you require additional
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationAIT - Austrian Institute of Technology
BIOMARKER DISCOVERY, BIOINFORMATICS, AND BIOSENSOR DEVELOPMENT Technology Experience AIT Austrian Institute of Technology Low-Emission Transport AIT - Austrian Institute of Technology Energy Health & Bioresources
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationInternational Conference on Biochemistry, Genetics & Molecular Research Theme: An Evolving Science of Life
International Conference on Biochemistry, Genetics & Molecular Research Theme: An Evolving Science of Life About the Conference: Gavin Conferences invites participants from all over the world to attend
More informationLessons from the EHRA Innovation Summit: How EHRA can help to clear the hurdles for getting innovative solutions reimbursed
Lessons from the EHRA Innovation Summit: How EHRA can help to clear the hurdles for getting innovative solutions reimbursed Frits W. Prinzen PhD Time, Costs The problem: innovation, but at what price?
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationIntroduction to Drug Development
Introduction to Drug Development Yves Geysels, PhD Head Clinical Research Operations, Belgium Past President of the Associoation of Clinical Research Professionals (ACRP) Board Member of the European Forum
More informationThe Genomic Transformation of Health
The Genomic Transformation of Health or: an introduction to the potential of genomics in healthcare Dr Tom Connor School of Biosciences and Systems Immunity University Research Institute Cardiff University
More informationMRC Stratified Medicine Initiative
MRC Stratified Medicine Initiative Jonathan Pearce Medical Research Council, Translational Programme Manager Pharmacogenetics and Stratified Medicine Network Conference : 14 th January 2015 Stratified
More informationPrecision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease
Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease Session #61, February 20, 2017 Jason Levine, MD, Assoc. Director of Clinical Informatics,
More informationORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationInternational Conference on Engineering Technology & Applied Sciences Theme: Discovery, Invention & Innovation of Technology
International Conference on Engineering Technology & Applied Sciences Theme: Discovery, Invention & Innovation of Technology About the Conference: Gavin Conferences invites participants from all over the
More informationEBE White Paper on Personalised Medicine
EBE White Paper on Personalised Medicine EBE is a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA Content p3 p4 p6 p6 p7 p9 p10 p11 p13 p14 Executive Summary
More informationIntroduction to Genomic Medicine Using Galaxy Platform (Workshop)
Introduction to Genomic Medicine Using Galaxy Platform (Workshop) INTRODUCTION : Genomics is "an emerging medical discipline that involves using genomic information about an individual as part of their
More information2017 Precision Medicine Study
2017 Precision Medicine Study www.himssanalytics.com Enabling better health through information technology. Precision Medicine Study Introduction DNA genetic testing companies such as Ancestry.com and
More informationMicrofluidics as an enabler for Medical Diagnostics
Microfluidics as an enabler for Medical Diagnostics Henne van Heeren, enablingmnt Microfluidics: The ability to create complex channel manifolds on a single substrate with no dead volume between connecting
More informationHealth in Europe: A Strategic Approach. Consultation Statement from the Secretariat of the Public Health Genomics European Network (PHGEN)
Health in Europe: A Strategic Approach Consultation Statement from the Secretariat of the Public Health Genomics European Network (PHGEN) The Public Health Genomics European Network (PHGEN) welcomes the
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationOpen Innovation March 2014
Open Innovation March 2014 Open innovation Necessity is the mother of all invention English Proverb ascribed to Plato. Is Open Innovation an idea born out of necessity to survive for big Pharma? Open innovation
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationDelivering on the Promise of Precision Medicine
Delivering on the Promise of Precision Medicine Bay Area Council Economic Institute Spring 2016 The Promise of Precision Medicine The Bay Area is one of the world s biggest hubs for innovation in research
More informationBIOSCIENTIA. Good outcomes are based on good values. Central lab services and biomarker analytics for clinical trials
BIOSCIENTIA Good outcomes are based on good values Central lab services and biomarker analytics for clinical trials BIOSCIENTIA Do you remember when...... US President Ronald Reagan appealed to Michail
More informationWhere are your medical records?
Where are your medical records? Abstract The world of medicine is changing rapidly. We are at the beginning of an era where we treat a patient for their particular condition and not just a general condition.
More informationOur website:
Biomedical Informatics Summer Internship Program (BMI SIP) The Department of Biomedical Informatics hosts an annual internship program each summer which provides high school, undergraduate, and graduate
More informationPrecision Medicine. Presented by:
Precision Medicine Presented by: Prepared Brendan FitzGerald For: Enabling better health through information technology. Healthcare Information and Management Systems Society (HIMSS) HIMSS is a global,
More informationAnalytics in Healthcare. Preparing for advance healthcare analytics
Analytics in Healthcare Preparing for advance healthcare analytics Connected Health From devices to data to patients and caregivers through to data analysis that addresses actionable insight, you need
More informationIntroduction to Bioinformatics
Introduction to Bioinformatics Richard Corbett Canada s Michael Smith Genome Sciences Centre Vancouver, British Columbia June 28, 2017 Our mandate is to advance knowledge about cancer and other diseases
More informationTowards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory
Towards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory Bull, 2012 Natalia Jiménez Lozano Business Development Manager BULL e-health Consultancy & Business Solutions Tlf: 913939253
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationIntroduction to Bioinformatics
Introduction to Bioinformatics Alla L Lapidus, Ph.D. SPbSU St. Petersburg Term Bioinformatics Term Bioinformatics was invented by Paulien Hogeweg (Полина Хогевег) and Ben Hesper in 1970 as "the study of
More informationComputational Biology
3.3.3.2 Computational Biology Today, the field of Computational Biology is a well-recognised and fast-emerging discipline in scientific research, with the potential of producing breakthroughs likely to
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationThe patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.
Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the
More informationWhat is biomedical science?
What is biomedical science? Biomedical science is the science at the heart of healthcare Everyone will use the services of biomedical scientists more than once during their life Samples taken by doctors
More informationAbout OMICS Group Conferences
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of
More informationMEDICAL PHYSICS (MED PHYS)
Medical Physics (MED PHYS) 1 MEDICAL PHYSICS (MED PHYS) MED PHYS/PHYSICS 265 INTRODUCTION TO MEDICAL PHYSICS Primarily for premeds and other students in the medical and biological sciences. Applications
More informationPersonalized Medicine
Personalized Medicine Dr. Pablo Mentzinis, Director Government Relations, SAP SE Courtesy by Dominik Bertram, Marc von der Linden, Péter Adorján, SAP June 2016 1. Traditional medicine vs. personalized
More informationrevent pandemics WaveGuide s connected health device makes waves: Breakthrough technology delivers rapid results to help About WaveGuide Corporation
Customer Stories: WaveGuide WaveGuide s connected health device makes waves: Breakthrough technology delivers rapid results to help revent pandemics Business needs - Better ways to diagnose patients and
More informationThe Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic
The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview
More informationCIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator
FP7 Health Partnering event 10 June 2011, Brussels International session CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator Translational Research CIBIR:
More informationPrecision Medicine in Sepsis
Precision Medicine in Sepsis Jean-Daniel Chiche, MD PhD jean-daniel.chiche@aphp.fr MICU & Dept Infection, Immunity & Inflammation Hôpital Cochin & Institut Cochin, Paris-F Sepsis 2017: a litany of failed
More informationLETI-HEALTH. Adrienne Pervès Deputy Director LETI Technologies for Biology and healthcare Department
Adrienne Pervès adrienne.perves@cea.fr Deputy Director LETI Technologies for Biology and healthcare Department LETI-HEALTH Micro- NanoTechnologies for Healthcare and Biology MISSION AND EXPERTISE Focused
More informationCancer Research UK submission to House of Lords Science and Technology Committee inquiry on Scientific Infrastructure. June 2013
Cancer Research UK submission to House of Lords Science and Technology Committee inquiry on Scientific Infrastructure June 2013 1. Every year around 300,000 people are diagnosed with cancer in the UK.
More informationQuo vadis Medical Industry?
Quo vadis Medical Industry? 18th December 2014 Karl Branzén Sweden has experienced the winds of change in the drug industry In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and
More informationThe road to the future: biomedical research paving the way towards precision medicine
The road to the future: biomedical research paving the way towards precision medicine Conference 24-25 November 2016 Celebrating 15 years of Biomedical Research at Eurac Eurac Research, Center for Biomedicine,
More informationThe International Consortium for Personalised Medicine
The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals
More informationImperial College London Key Research Themes for NBIT and FP7
Imperial College London Key Research Themes for NBIT and FP7 Professor Richard I Kitney Imperial College Research Systems and Software Solutions Advanced Information Systems (eg CISs) Systems Analysis
More informationTECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298
DIAGNOSTICS BUSINESS ANALYSIS SERIES: TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 By ADAMS BUSINESS ASSOCIATES March 2017. March 2017 ABA 298 1 Technologies, Products & Services
More informationEE 45X Biomedical Nanotechnology. Course Proposal
EE 45X Biomedical Nanotechnology 1 Introduction Jie Chen ECERF W6-019 492-9820 jchen@ece.ualberta.ca Oct. 15, 2008 The purpose of this document is to propose a new course in the area of Biomedical Nanotechnology
More informationTHE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org
THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters
More informationPERSONALISED MEDICINE FOR THE BENEFIT OF PATIENTS
PERSONALISED MEDICINE FOR THE BENEFIT OF PATIENTS CLEAR DIAGNOSIS TARGETED TREATMENT STRENGTHENED RESEARCH SUMMARY NATIONAL STRATEGY FOR PERSONALISED MEDICINE 2017-2020 FOREWORD Personalised Medicine
More informationPrecision Medicine Catapult
Precision Medicine Catapult Building on UK excellence - Growing the precision medicine industry April 2015 catapult.org.uk @PMCatapult Precision Medicine Catapult scale, quality, speed National innovation
More informationNew PET/CT from Siemens helps more patients benefit from premium technologies
Press Healthcare Erlangen, October 9, 2015 EANM 2015, Congress Center Hamburg (CCH) New PET/CT from Siemens helps more patients benefit from premium technologies Versatile new PET/CT system addresses a
More information